objectives Molecular characteristics of hepatitis B virus (HBV), such as genotype and genomic mutations, may contribute to liver-related morbidity and mortality. The association of these characteristics with liver fibrosis severity in sub-Saharan Africa is uncertain. We aimed to characterise molecular HBV features in human immunodeficiency virus (HIV)/HBV co-infected Nigerians and evaluate associations between these characteristics and liver fibrosis severity before and after antiretroviral therapy (ART) initiation.
Introduction
Hepatitis B virus (HBV) infects an estimated 240 million people worldwide with variable and complex clinical outcomes [1, 2] . Some of the highest rates of chronic HBV are seen in sub-Saharan Africa (SSA), where co-infection with human immunodeficiency virus (HIV) is also high. HIV has a detrimental effect on HBV infection, including increased risk of chronicity, liver fibrosis, hepatocellular carcinoma (HCC) and all-cause mortality [3] [4] [5] . The elements that influence liver fibrosis in HIV/HBV-infected patients are complex, including both host-and virus-specific factors. Certain HBV molecular characteristics, including genotype and specific viral mutations, have been associated with more advanced liver fibrosis, HCC, decreased response to therapy and fulminant hepatic failure in both HBV-mono-infected and HIV/HBV-co-infected patients [6] [7] [8] [9] [10] [11] [12] [13] .
Hepatitis B virus is a 3.2 kb circular, partially doublestranded DNA virus comprised of four partially overlapping open reading frames. HBV replicates by reverse transcription using a polymerase that lacks proof-reading ability, leading to mutations in the genome and sequence heterogeneity [7] . Based on this sequence heterogeneity, HBV has been classified into at least nine genotypes (A-I), which have distinct geographical distributions and variable clinical outcomes [6] [7] [8] [9] 14] . Similarly, mutations in specific regions of the HBV genome have also been associated with different clinical outcomes. More specifically, mutations in the basal core promoter (BCP) and precore (PC) regions have been found in association with hepatitis B e-antigen (HBeAg) negative chronic hepatitis, cirrhosis and HCC. Mutations in the preS1/preS2/S regions and the overlapping reverse transcriptase region have been associated with HCC, infection despite immunisation, failure of detection and drug resistance [10] [11] [12] [13] .
The majority of studies examining the association between genetic mutations and liver disease have been conducted in Asia/Europe and in patients infected with genotypes (GTs) A-D. There are very few molecular studies of HBV characteristics from Nigeria, despite it having the third highest global prevalence of HBV infection [15] . Of those few, most focused on viral evolution and diversity, or described specific mutations related to vaccine or detection escape [16] [17] [18] [19] [20] . More in-depth mutational analysis of HBV circulating in this region is important given the disproportionate mortality burden of viral hepatitis carried by western SSA and predominance of genotype E (GTE), which to date has been relatively understudied [21] . Furthermore, HCC occurs at higher rates and younger ages in this region; identifying potentially unique pathways of HBV disease progression in western SSA is critical to understanding the epidemic and its consequences [22, 23] .
The objectives of this study were to: (i) characterise the HBV genotype and prevalence of BCP/PC and preS1/ preS2/S mutations in antiretroviral therapy (ART)-na€ ıve HIV/HBV-co-infected patients in Jos, Nigeria; and (ii) evaluate associations between specific mutations and liver fibrosis severity before and after ART initiation.
Methods

Patient population and ethical considerations
This substudy was conducted in HIV/HBV-co-infected patients enrolled in a larger prospective cohort study of liver fibrosis in HIV-infected Nigerians before and after ART at the President's Emergency Plan for AIDS Relief (PEPFAR)/AIDS Prevention Initiative in Nigeria (APIN)-supported Jos University Teaching Hospital (JUTH) HIV Care and Treatment Center [24] . All patients were enrolled between July 2011 and February 2012. For this analysis, we included all HIV/HBV-co-infected adults (≥18 years), defined as ≥1 positive HBsAg (EIA assay; Sysmex). Exclusion criteria were current/prior ART for the treatment of HIV, HCV seropositivity, HCC or decompensated liver disease. Patients were recruited and enrolled after written informed consent; the study was approved by the Institutional Review Boards of JUTH and Northwestern University.
Clinical protocols and data collection
Patients were followed prospectively for three years. At study enrolment and annual study visits, thereafter, patients received a clinical assessment and laboratory studies. Clinical care of all HIV-infected patients at JUTH followed Nigerian and WHO 2010 guidelines [25, 26] . ART was provided free of charge by the Nigerian government along with regular monitoring and treatment/prevention of opportunistic infections. In 2012, HIV/HBVco-infected patients were initiated on tenofovir (TDF) plus lamivudine (3TC) or emtricitabine (FTC)-containing regimens at CD4+ T-cell count ≤350 cells/mm 3 or if evidence of chronic active hepatitis (ALT > 41 IU/ml in men and >31 IU/ml in women) regardless of CD4 count.
Patient demographic, clinical, laboratory and therapeutic data were collected and entered into a secure computerised database. Data included gender, age, body mass index (BMI), alcohol use (yes/no), clinical visit dates, ART regimen at initiation and follow-up, ART duration, and date of lost to follow-up and/or death, haemoglobin g/dl (Hgb), CD4+ T-cell count/mm 3 , alanine aminotransferase IU/L (ALT), HIV RNA copies/ml (Roche Cobas AmpliPrep TaqMan), HBV DNA IU/ml (Roche Cobas AmpliPrep TaqMan), HBeAg and anti-HBe, Transient elastography (TE) (FibroScan TM ; Echosens, France) were performed at baseline and at month 36 to assess liver fibrosis. Liver stiffness measurements (LSM) were considered reliable if ten successful measurements were obtained with a success rate >60%.
HBV sequencing
Plasma samples obtained from each patient for sequencing were stored at À80°C. HBV sequencing was conducted at the NUSeq Core Facility at Northwestern University, Chicago, IL. DNA was extracted from 200 ll of plasma using the QIAamp DNA Blood Mini Kit (Qiagen) and eluted in 100 ll of elution butter. Plasma samples with low HBV DNA (<2000 IU/ml) were ultracentrifuged at 236,4579 g for 1.5 h before DNA extraction with a 50 ll elution [27] .
Two regions of interest within the HBV genome were targeted for amplification and sequencing: the BCP/PC region and the complete S/partial P (S/P) region. When unable to successfully amplify or sequence the S/P region, a smaller region of the S ('short S') was amplified and sequenced to obtain genotype. The BCP/PC region (1742-1900 from EcoR1), S/P region (2535 to 1099 from EcoRI), and, when applicable, the short S region (467 to 704 from EcoRI) were amplified using nested PCRs with primers and protocols as previously described [28] [29] [30] [31] [32] . Further details regarding primers and reaction conditions are included in the Appendix S1.
Traditional capillary sequencing was performed using an ABI 3730 High Throughput DNA Sequencer (Applied Biosystems). The BCP/PC and short S regions were sequenced using second-round PCR primers. The S/P region was sequenced in three overlapping fragments using primers described by Vermeulen, et al., with minor adjustments noted in the Appendix S1 [30] . Forward and reverse sequences were obtained, and contigs for the BCP/PC and short S region were created using the Automated Contig Generator Tool [33] . The overlapping fragments of the S/P region were assembled using the Fragment Merger Tool [34] . Multiple sequence alignment was performed using GeneDoc [35] . Neighbor-joining phylogenetic trees with bootstrap support were constructed using Pipeline Tree Mail Tool and visualised by MEGA 7.0 [33, 36] . Genotyping was performed by phylogenetic analysis of the complete S/P region or the short S region, as available. DAMBE was used to calculate sequence diversity, and the Mutation Reporter Tool was used to identify mutations at specific loci [33, 37] .
Outcomes, definitions and statistical analysis
Baseline clinical characteristics were compared by MannWhitney U-test for continuous data and Chi-square test for categorical data. The primary outcomes of interest were baseline liver fibrosis severity and change in liver fibrosis between baseline and 36 months. Liver fibrosis was staged based on TE score using validated LSM cutoffs in HIV/HBV-co-infected patients: >5.9 kPa (Metavir F2 fibrosis), >7.6 kPa (F3) and >9.4 kPa (F4 fibrosis/cirrhosis) [38] . Univariate analyses were performed to assess for any associations between specific HBV mutations and baseline advanced fibrosis (≥F3) using logistic regression. Multivariable (MV) analyses were performed for characteristics with a P-value <0. 20 .
In secondary analyses, we evaluated associations between HBV mutations and HBV DNA levels, as well as changes in TE score and HBV DNA after ART. Change in TE score was assessed both as a binary and continuous outcome. The binary outcome was defined as a decline of ≥1 fibrosis stage (yes/no), using the aforementioned TE cut-offs. The per cent change in fibrosis was also modelled as a continuous dependent variable. Wilcoxon Signed Rank was used to compare related samples at different time points. A P-value of <0.05 was deemed statistically significant. Calculations were performed using SPSS v22.0 (IBM, Armonk, NY, USA).
Results
Clinical features of the cohort
Ninety-four HIV/HBV-co-infected patients were enrolled into the parent study. Baseline characteristics are shown in Table 1 . Patients had a median age of 32 (IQR 28-40) years were mostly females (60%) with a median CD4+ T-cell count of 265 (IQR 171-400) cells/mm 3 . The median log 10 HBV DNA was 1.6 (IQR 0-5.5) IU/ml, and 19 (20%) participants had reactive HBeAg. Median LSM score was 6.4 (IQR 4.7-8.7) kPa; 21 (22.1%) had LSM >9.4 kPa.
After enrolment, 82 (86.3%) patients initiated antiretroviral therapy (ART), primarily TDF-based (83.8%). Median follow-up during the study was 31 (IQR 28-33) months; 72 of 94 patients received a follow-up TE. Median ART duration between TE scans was 27.5 (IQR 19-31) months. Over the study period, median liver stiffness declined from 6.4 (IQR 4.7-8.7) kPa to 5.2 (IQR 4.1-6.6) kPa.
HBV genotype, phylogenetic analysis and sequence diversity
Sixty-nine of 94 patients had frozen, banked plasma samples available for amplification and sequencing. There were no significant differences in patient characteristics with and without banked specimens (Table 1) .
Forty-six patient samples were successfully genotyped based on sequencing of the complete or partial S region; we were unable to amplify the S region from 21 samples and did not obtain adequate sequencing data from two samples.
The complete S/partial P ('S/P,' nt 2535-1099) was successfully sequenced from 17 patients. Shorter S regions were successfully sequenced in an additional 29 patients: S region without preS1 or preS2 (nt 155-835) in four patients and the 'short S' segment (nt 467-704, encompassing amino acids 105-184 of the S region) in 25 patients. These S region sequences were genotyped by phylogeny. Forty-five of the sequences belonged to GTE, and the remaining one sequence belonged to genotype D (GTD). The 17 S/P sequences are shown in a neighbor-joining phylogram, rooted on genotype F, in Figure 1 . One sequence (JU120057) appears to be genotype D3, while the remaining 16 sequences belong to genotype E.
The intragroup divergence of the 16 genotype E sequences was 2.23% (AE1.07). Nucleotide diversity of the individual sequences, as compared to a genotype E consensus sequence, was strongly associated with age (b = 0.582, P = 0.018). There were no associations between sequence diversity and HIV RNA, CD4+ T-cell count and HBV DNA level in univariate analyses.
Sequencing results
PreS1 and preS2 were sequenced in 17 patients, and further analysed in the 16 GTE patients. There were no preS1 start codon mutations, preS1 deletions or preS2 start codon mutations. Six (37.5%) of the samples had preS2 deletions, ranging from 1 to 11 amino acids in length. One patient had a preS2 glycine insertion after the third amino acid, and one patient had the F22S mutation.
The S region, including the 'a' determinant (amino acids 124-147), was sequenced in 42 GTE samples. Overall, 12 (26.7%) GTE patients had at least one mutation in the 'a' determinant region. The most frequent mutations in this region were sT131P (4/45) and sS140L (3/45). One well-described vaccine-escape mutation, sG145R, occurred in two patients. Outside of the 'a' determinant, common mutations occurred at residues 164 (sE164G in 5/46 and sE164A in 1/46), 110 (sI110L in 5/ 46) and 184 (sA184V in 2/46).
The complete or partial reverse transcriptase (RT) region of the Pol gene was analysed in all 47 patients. No clinically significant mutations associated with drug resistance were identified.
The BCP/PC region (nt 1742-1900) was successfully sequenced in 35 patients. Fifteen (43%) had the double A1762T/G1764A mutation ('TA mutation') in the BCP region; an additional patient had only G1764A. Six patients had C1766G, and four patients had T1753C. Twenty patients (57%) had PC G1896A mutations, and 12 (34%) had PC G1899A mutations.
Factors associated with baseline liver fibrosis severity, HBV DNA and HBeAg
PreS2 insertion-deletion mutants ('indels') were significantly associated with advanced fibrosis/cirrhosis (LSM > 7.6 kPa) in the univariate (UV) analysis ( Table 2) . This relationship was strongest with five patients who had preS2 indels between preS2 amino acid 1-25, in the B-cell epitope (P = 0.017, data not shown). There was no relationship between preS2 indels and patient age, HBV DNA level, HBeAg status, HIV RNA level or CD4+ T-cell count. The relationship between preS2 mutations and liver fibrosis severity was statistically significant in the multivariable analysis, controlling for age in the final model, albeit with a P-value of 0.047 (Table 2 ). There were no statistically significant associations between the presence of 'a' determinant mutations and baseline liver fibrosis severity or HBV DNA.
We saw a higher frequency of the 1762/1764 'TA mutation' and a lower frequency of the G1896A mutation in patients with HBV DNA ≥ 20 000 IU/ml, but these differences were not statistically significant (data not shown). There were no associations between any BCP/PC mutants and baseline liver fibrosis severity, HBV DNA, patient age, HIV RNA or CD4+ T-cell counts.
The majority of the BCP/PC mutations were found in HBeAg-negative patients [BCP 'TA': 12/30 eAg (À), 3/5 eAg (+); PC G1896A: 19/30 eAg (À), 1/5 eAg (+)], although analysis is limited by very low number of eAg+ sequences (n = 5), and this was not statistically significant. Notably, all three HBeAg (+) patients with the double TA mutation, including one patient also with G1896A, experienced HBeAg seroconversion over the study period. 
Factors associated with fibrosis change and HBV virologic control after ART
The percentage of HIV/HBV-co-infected patients with cirrhosis declined from approximately 22% (21/95) to 11% (8/72). A total of 52 patients (72%) patients experienced a decline in LSM, and 29 (40%) decreased by at least one fibrosis stage. Conversely, 8/72 (11%) patients had increases in liver stiffness that classified them into a higher fibrosis stage. HBV DNA levels decreased from a median of 1.6 to 0 log 10 IU/ml. Fifty (69.4%) patients achieved an undetectable HBV DNA level (<20 IU/ml) at the three-year follow-up period; for comparison 51 (70.8%) achieved an undetectable HIV RNA (<200 copies/ml).
Features associated with a lack of decline in fibrosis stage are shown in Table 3 . The MV model, after controlling for baseline liver stiffness, identified three main factors associated with stable/progressive liver fibrosis after ART initiation: BMI, baseline CD4+ T-cell count and virologic control of HIV RNA at follow-up. There were no significant associations between specific HBV mutations and fibrosis change. Results were similar when fibrosis change was measured as a continuous outcome. No HBV mutations were associated with a detectable HBV DNA (≥20 IU/ml) at the 36-month follow-up in UV or MV analyses.
Discussion
We report results from the first published study evaluating molecular characteristics of HBV in relationship to liver fibrosis before and after ART initiation in HIV/HBV-coinfected patients. We identified a high frequency of preS2 deletions (6/16, 37.5%). PreS1 and preS2 mutations have been associated with more severe liver disease, including fulminant hepatitis, cirrhosis and HCC. HCC, in turn, appears to occur at high frequencies and at younger ages in certain sub-Saharan cohorts than in other populations [22, 39] . PreS2 mutants may cause hepatocellular toxicity due to the overproduction and accumulation of mutated envelope proteins, leading to endoplasmic reticulum stress, DNA damage and genomic instability [13] . In a large study evaluating the frequency of HBV genome mutations in pre-ART HIV/HBV-and HBV-mono-infected individuals, preS2 mutations were found more commonly in coinfected patients (12/82, 14.6% vs. 2/60, 3.3%, P = 0.04) [40] . This finding was independent of genotype, although this cohort did not include any patients with GTE infection. A molecular study involving multiple countries in West Africa found preS2 deletions in 30.6% (33/108), including 15/35 (42.8%) from Nigeria with unknown HIV status [18] . Other studies including patients from SSA or with GTE have reported lower frequencies of preS2 deletions, and the effect of HIV infection on the presence of these mutations in this region is unclear [29, 32, 41, 42] . In this study, preS2 indel mutations were associated with baseline liver fibrosis severity, but not fibrosis regression; liver fibrosis information was not available for the GTE patients in the prior studies.
We found a relatively high number of mutations in the 'a' determinant region in this population (12/42, 26.7%) . The 'a' determinant is critical for antibody recognition. HBsAg variants not recognised by antibodies can cause infection despite vaccination or treatment with hepatitis B immunoglobulin (HBIG); additionally commercial assays may fail to detect certain HBsAg mutants [43] [44] [45] . Interestingly, a study from Nigeria published in 2001 only identified 'a' determinant mutations in one of 20 (5%) patients [16] . Studies in other parts of the world have demonstrated increasing 'a' determinant mutations over time, likely related to the expansion of hepatitis B vaccination [45] . In Nigeria, the hepatitis B vaccine was introduced in 1995, however not widely available until 2004 [46, 47] . Patients in this study were all born prior to 2004, although vaccination history was not available in our study patients.
More recent studies from Nigeria have reported immune escape mutants in pregnant women, asymptomatic patients and HBsAg detection failures related to 'a' mutations [19, 20] . In this cohort, we found two patients with the well-described G145R mutation, as well as several patients with other mutations potentially leading to immune escape (including 'a' determinant sites 126, 129, 130, 131 and 144). The most common S region mutants in our cohort occurred outside the 'a' determinant, at amino acids 110 and 164. The clinical significance of these mutations is unknown, although s164 mutants have been found in association with negative HBsAg testing [45, 48] . Similar frequencies of these mutations have been seen in other GTE cohorts [42, 49] . Additionally, two of our patients had sA184V, which was shown to impede detection by commercial assays of HBsAg in GTE-infected Nigerian patients [20] . As HBV is hyperendemic in western SSA and prevalence is rising, knowledge of the genotype and predominant HBV molecular variants circulating in this region is critical given the potential impact on diagnostic capabilities and vaccine effectiveness [18, 21] .
We found a high frequency of the 'TA' mutation, (15/ 35, 43%) and G1896A mutation (20/35, 57%); mutations in these regions affect the production of HBeAg. The double A1762T/G1764A ('TA' mutation) in the BCP region affects mRNA transcription and decreases HBeAg production [50] . In the PC region, the G1896A mutation creates a stop codon in the PC gene abolishing HBeAg expression [51] . The majority of BCP/PC mutations in this cohort occurred in e-antigen negative patients or eantigen positive patients who subsequently seroconverted to anti-HBe, a phenomenon previously reported [11, 52] . The TA mutation frequency in this study was higher than that observed in other studies from western Africa, although the frequency of G1896A was similar [42, [53] [54] [55] . Interestingly, rates of HBeAg seropositivity [19 (20. 2%)] were significantly lower in this cohort than those reported in two large European and multinational HIV/HBV-co-infected cohorts (Lacombe, et al.: 161/301, 53.5%; Thio, et al.: 57/113, 50.4%), although these studies included few patients with GTE infection [9, 56] . HBeAg positivity in predominantly HIV-negative GTE West African cohorts appears quite variable, ranging from 6.8% to 34% in three studies [53, 55, 57] . While data from HIV/HBV-co-infected cohorts in West Africa are scarce, a previous study from Jos found a significantly higher HBeAg seropositivity in co-infected patients than mono-infected (28/100 vs. 15/100, P = 0.03). It is uncertain whether HIV has any effect on BCP/PC mutations, although two (non-GTE) comparative studies found more frequent BCP mutants in HIV-negative patients in certain genotypes [40, 58] . A novel PC-1G mutant has been identified in HIV/HBV-co-infected patients with GTA and associated with higher HBV DNA levels, which we did not identify in this cohort [40, 59] . Basal core promoter, and to a lesser degree PC, mutations have also been associated with hepatocellular carcinoma and liver cirrhosis, but also isolated in patients with mild or asymptomatic disease [10, 11, 60] . The effects of these mutations may differ depending HBeAg status: eAg (+) patients with BCP/PC mutants have been associated with more liver inflammation, but also lower HBV DNA levels than their eAg (À) counterparts [60, 61] . We found no association between BCP or PC mutations and baseline HBV DNA levels, baseline liver cirrhosis, or liver fibrosis change.
Overall, we did not find any significant associations between specific HBV mutants and liver disease progression or HBV virological suppression after the initiation of ART. HBV virologic suppression after ART initiation did not impact fibrosis regression, whereas HIV virologic suppression (RNA <200 copies/ml) was significantly associated with fibrosis regression.
To our knowledge, this study is one of first to assess HBV mutations in HIV/HBV-co-infected patients in West Africa and examine the effect of specific mutations on long-term clinical and virological outcomes. It provides information on the prevalence of mutations within one of the most important and least studied HBV genotypes, adding to the knowledge required to optimise detection and treatment of HBV in this population. Important limitations of this study include its observational design and exclusion of HBV-mono-infected patients. Also, LSM is an imperfect measure of liver fibrosis, and its interpretation may differ based on disease, particularly for fibrosis stages <F4 [62] . This may impact the use of TE in multifactorial liver disease. Along those lines, we were not able to examine other potential contributors to liver disease, including hepatitis D virus (HDV), quantitative alcohol intake, other hepatotoxic medications or herbs or aflatoxin. The small number of sequenced plasma samples and issue of multiple comparisons also limit the strength of our conclusions. It is possible that the relationship between preS2 mutations and liver fibrosis severity is due to chance alone; however, these mutations have previously been associated with severe liver disease with a biologically plausible mechanism [12, 13] . Lastly, we did not assess HBV quasi-species populations, which may impact the clinical manifestations of viral mutations [52, 63] .
In conclusion, a high frequency of BCP, PC, 'a' determinant and preS2 mutations were observed in this ARTna€ ıve GTE-infected HIV/HBV cohort. While preS2 mutations were associated with advanced fibrosis and cirrhosis at baseline, none of the mutations were associated with fibrosis progression or failure to suppress HBV after ART initiation. This suggests that the presence of these viral mutations at baseline does not negatively impact liver fibrosis regression after initiation of ART.
